Milestone Pharmaceuticals has enrolled the first European patient in its ReVeRA-301 Phase 3 trial testing etripamil nasal spray for atrial fibrillation with rapid ventricular rate (AFib-RVR). This trial aims to evaluate a self-administered treatment option that could reduce symptoms and hospital visits for AFib-RVR patients. The study uses the same FDA-approved 70 mg dose regimen as CARDAMYST for PSVT and targets about 150 patients globally. Successful results could lead to a new, convenient treatment for managing AFib-RVR outside hospital settings.
Milestone Pharmaceuticals' clinical trial enrollment is noted here with Pluang's health sector market data for context. As of Oct 09, 2026 17:51 WIB, 66 of 128 priced health-sector US stocks rose while 56 fell. Among notable movers, Bio-Rad Laboratories (BIO) traded at USD 375.02 with a 4.06% increase, Definium Therapeutics (DFTX) at USD 35.40 rose 3.57%, and Heron Therapeutics (HRTX) at USD 0.37 gained 3.29%.
At Malaysia's IGEM 2026, Sigenergy showcased its latest AI-driven energy technologies, including smart storage and inverter systems, highlighting its role in advancing sustainable energy. The company also signed MOUs with local partners Milieu and YT...
NEAR Protocol traded at $4.93 on October 10, 2026, rising 8.6% after a sharp 16.37% drop the day before. Despite a 97.5% gain over 30 days, the price has been volatile and flat over the past two weeks, fluctuating within a narrow range. This volatili...
U.S. bitcoin spot ETFs reversed two days of outflows with $21.13 million in net inflows on October 9, 2026. Among 12 ETFs, IBIT and HODL attracted inflows of $22.38 million and $2.33 million respectively, while FBTC saw outflows of $3.58 million. The...
U.S. spot Ethereum ETFs experienced net outflows for the ninth consecutive trading day on October 9, with $56.1 million withdrawn, narrowing from $72.54 million the previous day. This streak began on September 29, reflecting ongoing investor caution ...
Two addresses on the Aster decentralized exchange (DEX) currently hold long positions totaling 7.2 million SYN tokens, valued at $1.34 million. These positions have unrealized gains of approximately $450,000, with the highest reported return reaching...
